PT1286962E - Compostos de 2-etil- e 2-etilideno-19-nor-vitamina d - Google Patents

Compostos de 2-etil- e 2-etilideno-19-nor-vitamina d

Info

Publication number
PT1286962E
PT1286962E PT01939792T PT01939792T PT1286962E PT 1286962 E PT1286962 E PT 1286962E PT 01939792 T PT01939792 T PT 01939792T PT 01939792 T PT01939792 T PT 01939792T PT 1286962 E PT1286962 E PT 1286962E
Authority
PT
Portugal
Prior art keywords
compounds
ethylidene
vitamin
activity
ethyl
Prior art date
Application number
PT01939792T
Other languages
English (en)
Inventor
Hector F Deluca
Rafal R Sicinski
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of PT1286962E publication Critical patent/PT1286962E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
PT01939792T 2000-05-31 2001-05-31 Compostos de 2-etil- e 2-etilideno-19-nor-vitamina d PT1286962E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20819900P 2000-05-31 2000-05-31

Publications (1)

Publication Number Publication Date
PT1286962E true PT1286962E (pt) 2008-07-30

Family

ID=22773624

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01939792T PT1286962E (pt) 2000-05-31 2001-05-31 Compostos de 2-etil- e 2-etilideno-19-nor-vitamina d

Country Status (15)

Country Link
US (5) US6806262B2 (pt)
EP (1) EP1286962B1 (pt)
JP (1) JP4022141B2 (pt)
AT (1) ATE399151T1 (pt)
AU (2) AU6527201A (pt)
BR (1) BR0111173A (pt)
CA (1) CA2410880C (pt)
DE (1) DE60134549D1 (pt)
DK (1) DK1286962T3 (pt)
ES (1) ES2309069T3 (pt)
IL (1) IL152942A (pt)
MX (1) MXPA02011820A (pt)
NZ (1) NZ522909A (pt)
PT (1) PT1286962E (pt)
WO (1) WO2001092221A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
EP1219599B1 (en) * 1999-08-27 2010-03-31 Hiroaki Takayama Vitamin d derivatives having substituents at the 2 alpha-position
US20030018017A1 (en) * 2001-01-25 2003-01-23 Deluca Hector F. Method of treatment of type I diabetes
ES2276062T3 (es) * 2002-03-29 2007-06-16 Wisconsin Alumni Research Foundation Metodo para sintetizar 1-alfa-hidroxi-2-metilen-19-nor-homopregnacalciferol.
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
WO2004033420A1 (ja) * 2002-10-10 2004-04-22 Chugai Pharmaceutical Co Ltd ２,２−ジ置換−１α，２５−ジヒドロキシ−１９−ノルビタミンＤ誘導体
WO2004067504A1 (ja) * 2003-01-31 2004-08-12 Chugai Seiyaku Kabushiki Kaisha ２位置換ビタミンｄ誘導体
RU2317992C2 (ru) 2003-02-25 2008-02-27 Кей Эн Си Лэборэтериз Ко., Лтд. Новые промежуточные соединения для синтеза производных витамина d
GB0305332D0 (en) * 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
EP1613588B1 (en) * 2003-04-10 2012-05-09 Wisconsin Alumni Research Foundation 2-propylidene-19-nor-vitamin d compounds
ES2277293T3 (es) * 2003-07-03 2007-07-01 Wisconsin Alumni Research Foundation 2-metilen-19-nor-20(s)-25-metil-1-alfa-hidroxicalciferol y sus usos.
ATE537834T1 (de) * 2003-08-20 2012-01-15 Wisconsin Alumni Res Found 2-methylen-19-nor-vitamin d2-verbindungen
NZ545632A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of frailty, muscle damage or sarcopenia
MXPA06003156A (es) * 2003-09-19 2006-06-05 Pfizer Prod Inc Derivados de 2-alquiliden-19-nor-vitamina d para el tratamiento de osteopenia u osteoporosis masculina.
WO2005027928A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
US7214670B2 (en) * 2003-09-24 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
JP2008519808A (ja) 2004-11-12 2008-06-12 ビオエクセル エスピーエー 膀胱癌治療のためのビタミンｄ誘導体及び抗増殖薬の併用
NZ555281A (en) * 2004-11-22 2011-01-28 Wisconsin Alumni Res Found 2-methylene-19,26,27-trinor-(20s)-1alpha-alpha-hydroxyvitamin D3 and its uses
EP1846370B1 (en) 2004-11-22 2010-06-02 Wisconsin Alumni Research Foundation 2-METHYLENE-19-NOR-1&agr;-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES
MX2007006263A (es) * 2004-11-22 2007-07-10 Wisconsin Alumni Res Found Analogos 2a-metil y 2??-metil de 19,26,27-trinor-(20s)-1a- hidroxivitamina d3 y sus usos.
JP2008520706A (ja) * 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２α−メチル−１９−ノル−１α−ヒドロキシ−ホモプレグナカルシフェロール及びその使用
AU2005309804B9 (en) * 2004-11-22 2011-12-08 Wisconsin Alumni Research Foundation 2alpha-methyl-19-nor-(20S)-1alpha-hydroxy-bishomopregnacalciferol and its uses
US7241909B2 (en) * 2005-05-03 2007-07-10 Wisconsin Alumni Research Foundation 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
WO2007117563A2 (en) 2006-04-05 2007-10-18 Wisconsin Alumni Research Foundation 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and use thereof
US20090281340A1 (en) * 2006-04-05 2009-11-12 Deluca Hector F 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof
JP2010505739A (ja) * 2006-04-06 2010-02-25 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１α，２５−ジヒドロキシ−１９，２１−ジノルビタミンＤ３類縁体およびその使用
JP2009533483A (ja) * 2006-04-06 2009-09-17 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１α，２５−ジヒドロキシ−１８，１９，２１−トリノルビタミンＤ３およびその使用
EP2021320A2 (en) * 2006-04-06 2009-02-11 Wisconsin Alumni Research Foundation 2-substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof
CA2662992A1 (en) * 2006-09-28 2008-04-03 Wisconsin Alumni Research Foundation 2-methylene-(20r,25s)-19,27-dinor-(22e)-vitamin d analogs
NZ575159A (en) * 2006-09-28 2012-04-27 Wisconsin Alumni Res Found 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US8222236B2 (en) * 2008-07-10 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
WO2011119622A1 (en) * 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1α,25- DIHYDROXYVITAMIN D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
AU2011232633B2 (en) * 2010-03-23 2014-05-29 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1alpha,25- dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22- dimethyl-1alpha,25-hydroxyvitamin D3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
NZ232734A (en) 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
EP0474517B1 (en) 1990-09-07 1998-11-18 Wisconsin Alumni Research Foundation Novel use of 1alpha-hydroxylated-19-nor-vitamin D compounds to treat psoriasis
AU650751B2 (en) 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
ZA924811B (en) 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
JP2898882B2 (ja) 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
US5565589A (en) 1993-11-03 1996-10-15 Wisconsin Alumni Research Foundation 17-formyl-5,6-trans-vitamin D compounds
US5428029A (en) 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
WO1996001811A1 (en) 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives
EP0793649B1 (en) 1994-11-21 1999-02-03 Wisconsin Alumni Research Foundation 18,19-dinor-vitamin d compounds
US5877168A (en) 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
IL118156A (en) 1995-05-09 2001-08-26 Duphar Int Res Vitamin d compounds, their preparation and pharmaceutical compositions containing them
JP3344726B2 (ja) 1995-06-06 2002-11-18 メルク エンド カンパニー インコーポレーテッド 無水アレンドロネート一ナトリウム塩製剤
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds

Also Published As

Publication number Publication date
US20050282789A1 (en) 2005-12-22
NZ522909A (en) 2004-09-24
US20050043281A1 (en) 2005-02-24
ES2309069T3 (es) 2008-12-16
BR0111173A (pt) 2003-04-29
US7141558B2 (en) 2006-11-28
EP1286962B1 (en) 2008-06-25
MXPA02011820A (es) 2003-04-10
EP1286962A1 (en) 2003-03-05
DK1286962T3 (da) 2008-10-06
JP2004501114A (ja) 2004-01-15
US20080032956A1 (en) 2008-02-07
JP4022141B2 (ja) 2007-12-12
CA2410880C (en) 2009-03-03
IL152942A (en) 2007-09-20
ATE399151T1 (de) 2008-07-15
AU2001265272B2 (en) 2006-08-17
US20030013691A1 (en) 2003-01-16
US20070088008A1 (en) 2007-04-19
US7468361B2 (en) 2008-12-23
DE60134549D1 (de) 2008-08-07
US6806262B2 (en) 2004-10-19
US6992074B2 (en) 2006-01-31
CA2410880A1 (en) 2001-12-06
US7300925B2 (en) 2007-11-27
IL152942A0 (en) 2003-06-24
AU6527201A (en) 2001-12-11
WO2001092221A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
AU6527201A (en) 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
NZ514574A (en) Novel method of treatment
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
IL133585A0 (en) Soluble prodrugs of paclitaxel
CR7420A (es) Composiciones farmaceuticas que comprenden uno o varios esteroides, uno o varios componentes de tetrahiidrofolatos y vitamina b12
AR008853A1 (es) Nuevos compuestos farmaceuticamente activos, su uso en la fabricacion de medicamentos, metodo de tratamiento, composicion farmaceutica, compuestosintermediarios y proceso para la fabricacion de dichos compuestos
WO2001074839A3 (en) Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use
FI972744A0 (fi) Aminohappokokoonpanoja ja niiden käyttö kliinisessä ravinnossa
EP1098642A4 (en) METHOD FOR TREATING CONDITIONS MODULATED BY LACTOSYLCERAMIDES
JPS55136229A (en) Adjustment of bone metabolism in warm-blooded animal and drug for it
ATE176462T1 (de) 18,19-dinor-vitamin-d-derivate
EP1656157A4 (en) 2-METHYLENE-19-NOR-VITAMIN D2 COMPOUNDS
IL145122A0 (en) C16 unsaturated fp-selective prostaglandin analogs
EP1524264A3 (en) 2-ethylidene-19-nor-vitamin D compounds
DE69523914D1 (en) Pyridylbisphosphonate als therapeutische wirkstoffe
AU2001284657B2 (en) Use of vitamin d derivatives as bone resorption inhibitors
WO2005056520A8 (en) Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
RU2001131557A (ru) Аналоги витамина D и их фармацевтическое использование
EP0444899A3 (en) Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation
Panebianco et al. Use of disphosphonates in the treatment of osteoporosis in thyroidectomized patients on levothyroxin replacement therapy
CA2304821A1 (en) Osteoblast-specific mitogens and drugs containing such compounds
EP0653209A4 (en) MEDICINAL PRODUCTS FOR INFLAMMATORY COLON DISEASES.
HUT73500A (en) Use of benzydamine for producing pharmaceutical compositions for treatment of pathological conditions caused by tnf
ES468967A1 (es) Un procedimiento para la preparacion de d-homoesteroides
ATE212352T1 (de) Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate